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The retinal pigment epithelium (RPE) is an specialized epithelium lying in the interface between the neural retina and the
choriocapillaris where it forms the outer blood-retinal barrier (BRB). The main functions of the RPE are the following: (1)
transport of nutrients, ions, and water, (2) absorption of light and protection against photooxidation, (3) reisomerization of
all-trans-retinal into 11-cis-retinal, which is crucial for the visual cycle, (4) phagocytosis of shed photoreceptor membranes, and
(5) secretion of essential factors for the structural integrity of the retina. An overview of these functions will be given. Most
of the research on the physiopathology of diabetic retinopathy has been focused on the impairment of the neuroretina and the
breakdown of the inner BRB. By contrast, the eﬀects of diabetes on the RPE and in particular on its secretory activity have received
less attention. In this regard, new therapeutic strategies addressed to modulating RPE impairment are warranted.
1.Introduction
The retinal pigment epithelium (RPE) is a monolayer of
pigmented cells situated between the neuroretina and the
choroids. The RPE is of neuroectodermal origin and is
thereforeconsideredtobepartoftheretina.Theapicalmem-
brane of the RPE faces the photoreceptor’s outer segments
and its basolateral membrane faces Bruch’s membrane,
which separates the RPE from the fenestrated endothelium
of the choriocapillaris (Figure 1). The RPE constitutes the
outer blood-retinal barrier (BRB). The inner BRB is mainly
constituted by endothelial cells. Tight junctions between
neighbouring RPE cells and neighbouring endothelial cells
are essential in the strict control of ﬂuids and solutes that
cross the BRB as well as in preventing the entrance of
toxic molecules and plasma components into the retina.
Therefore, this sealing function is essential for the integrity
of the retina [1].
The main functions of the RPE are the following: (1)
Transportofnutrients,ions,andwater(2)absorptionoflight
and protection against photooxidation, (3) reisomerization
of all-trans-retinal into 11-cis-retinal, which is a key element
of the visual cycle, (4) phagocytosis of shed photoreceptor
membranes, and (5) secretion of various essential factors for
the structural integrity of the retina.
Apart from these functions, the RPE stabilizes ion
composition in the subretinal space, which is crucial for the
maintenance of photoreceptor excitability [2]. In addition,
the RPE contributes to the immune privileged status of
the eye as part of the BRB and by the secretion of
immunosuppressive factors inside the eye. In recent years
it has become clear, mainly from in vitro studies, that
RPE cells play an important role in immune responses by
the expression of major histocompatibility complex (MHC)
molecules, adhesion molecules, FasL and cytokines [3]. With
these diﬀerent complex functions, the RPE is essential for2 Journal of Biomedicine and Biotechnology
visual function. A failure of any one of these functions can
leadtodegenerationoftheretina,lossofvisualfunction,and
blindness.
Diabetic retinopathy (DR) remains the leading cause
of blindness among working-age individuals in developed
countries [4]. Whereas proliferarive diabetic retinopathy
(PDR) is the commonest sight-threatening lesion in type
1 diabetes, diabetic macular edema (DME) is the primary
cause of poor visual acuity in type 2 diabetes. Because of the
high prevalence of type 2 diabetes, DME is the main cause
of visual impairment in diabetic patients [5]. In addition,
DME is almost invariably present when PDR is detected in
type 2 diabetic patients [6]. Neovascularization due to severe
hypoxia is the hallmark of PDR whereas vascular leakage
due to the breakdown of the blood retinal barrier (BRB)
is the main event involved in the pathogenesis of DME
[7, 8]. Most of the research on the physiopathology of DR
has been focused in the impairment of the neuroretina and
the breakdown of the inner BRB. By contrast, the eﬀects of
diabetes on the RPE have received less attention.
In the following sections the functions of the RPE
mentioned above will be described in more detail, and the
deleterious eﬀects of diabetes will be summarized. Although
there is growing evidence pointing to RPE as an active
secretorepithelium,itseemsthatthisimportantfunctionhas
beenlessrecognized.Forthisreason,thisreviewwillfocuson
this essential propriety of RPE and its impairment in DR.
2.TransepithelialTransport
In one direction, the RPE transports electrolytes and water
from the subretinal space to the choroid, and in the other
direction, the RPE transports glucose and other nutrients
from the blood to the photoreceptors.
2.1. Transport from Blood to Photoreceptors. The RPE takes
up nutrients such as glucose, retinol, ascorbic acid, and fatty
acids from the blood and delivers these nutrients to the
photoreceptors.
To transport glucose, the RPE contains high amounts of
glucose transporters in both the apical and the basolateral
membranes. Both GLUT1 and GLUT3 are highly expressed
in the RPE [9–11]. GLUT3 mediates the basic glucose
transport while GLUT1 is responsible for inducible glucose
transport in response to diﬀerent metabolic demands.
Another important function of the RPE is the transport
of retinol to ensure the supply of retinal to the photorecep-
tors. The bulk of the retinal is exchanged between the RPE
and the photoreceptors during the visual cycle in which all-
trans-retinolistakenupfromthephotoreceptors,isomerized
to 11-cis-retinal, and redelivered to photoreceptors [12].
Delivery of fatty acids such as docosahexaenoic acid
(DHA) to the photoreceptors is a third kind of transport
of importance for visual function [13]. DHA is an essential
omega-3 fatty acid that cannot be synthesized by neural
tissue but is required as structural element by membranes
of neurons and photoreceptors. DHA is synthesized from
its precursor, linolenic acid, in the liver and transported in
the blood bound to plasma lipoprotein where it is taken
up in a concentration-dependent manner [1, 14]. Apart
from the RPE’s functional integrity, DHA is the precursor of
neuroprotectinD1(NPD1),adocosatrienethatprotectsRPE
cells from oxidative stress [15, 16].
Recently it has been demonstrated that high glucose
downregulates GLUT-1 by Akt pathway activation mediated
by the PKC-oxidative stress signaling pathway in ARPE cells
(a spontaneously immortalized line of RPE cells) [17]. In
addition, the transport of retinol may be altered due to a
downregulation of the interstitial retinol binding protein
(IRBP) that occurs in diabetic patients (see below). Finally
an impairment of the transport of ascorbic acid also exists
in the presence of hyperglycemia, thus limiting the RPE’s
antioxidant defence [18, 19]. To the best of our knowledge,
there is no information regarding the potential eﬀects of
diabetes on NPD1 or its precursor DHA.
2.2. Transport from Subretinal Space to Blood. The RPE
transports ions and water from the subretinal space or apical
sidetothebloodorbasolateralside[1].TheNa+-K+-ATPase,
which is located in the apical membrane, provides the energy
for transepithelial transport [20–23].
There is a large amount of water produced in the retina,
mainly as a consequence of the large metabolic turnover
in neurons and photoreceptors. Furthermore, intraocular
pressureleadstoamovementofwaterfromthevitreousbody
into the retina. This establishes the need for the constant
removal of water from the inner retina to the choriocapillaris
[24]. Water in the inner retina is transported by M¨ uller cells,
and water in the subretinal space is eliminated by the RPE
[25, 26]. Constant elimination of water from the subretinal
space produces an adhesion force between the retina and the
RPE that is lost by inhibition of Na+-K+-ATPase by ouabain
[27]. The transport of water is mainly driven by a transport
of Cl− and K+ [24, 28–30].
Tight junctions establish a barrier between the subretinal
spaceandthechoriocapillaris[31,32].Paracellularresistance
is 10 times higher than transcellular resistance, classifying
the RPE as a tight epithelium [33, 34]. For this reason,
water cannot pass through the paracellular transport route
and water transport occurs mainly by transcellular pathways
facilitated by aquaporin-1 [35–37].
Recently we have found that high glucose concentrations
result in a reduction of permeability in ARPE-19 cells [38]
that was unrelated to tight junction (occludin, ZO-1 and
claudin-1) changes. In this regard, in cultured bovine RPE
cells it has been demonstrated that hyperglycemia induces a
loss of Na+/K(+)-ATPase function, which responds to aldose
reductaseinhibitortreatment[39].Therefore,hyperglycemia
could impair the transport of water from subretinal space to
the choriochapilaris and, consequently, might contribute to
DME development.
At present, there is no information regarding the poten-
tial eﬀects of diabetes on aquaporin expression in the RPE.
3. Absorption of Light and Protection
againstPhotooxidation
The retina is the only neural tissue that has a direct and
frequent exposure to light. This circumstance favours theJournal of Biomedicine and Biotechnology 3
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Figure 1: Retinal section of the retina showing the location of the retinal pigment epithelium (RPE). In the box are listed the main functions
of RPE.
photooxidation of lipids which become extremely toxic to
retinalcells[40].Inaddition,theretinaisthepartofthebody
that proportionally consumes more oxygen, thus generating
ah i g hr a t eo fr e a c t i v eo x y g e ns p e c i e s( R O S ) .T h eR P Ei s
essential in counterbalancing the high oxidative stress that
exists in the retina, and it does this by means of three lines of
defence.
The ﬁrst line is the absorption and ﬁltering of light.
For this purpose, the RPE contains a complex composition
of various pigments (i.e., melanin, lipofucsin) that are
specialized to diﬀerent wavelengths and special wavelength-
dependent risks [41–43]. The second line of defence is
made by antioxidants. As enzymatic antioxidants, the RPE
contains high amounts of superoxide dismutase [44–47]
and catalase [45, 48]. As nonenzymatic antioxidants, the
RPE accumulates carotenoids, such as lutein and zeaxanthin
[42, 43] or ascorbate [42, 49]. In addition, glutathione
and melanin are important contributors to antioxidant
defence.
DR is characterized by reduced levels of molecules with
antioxidant activity such as glutathione [50, 51], superoxide
dismutase (SOD) [50, 52], and ascorbic acid [18, 53], thus
favouring retinal tissue damage induced by oxidative stress.
4. Visual Cycle
In vertebrate retina, vision is initiated and maintained by the
photolysis and regeneration, respectively, of light sensitive
pigments in the disk membranes of the photoreceptor outer
segments. This cyclical process depends on an exchange of
retinoids between the photoreceptors and the RPE.
Light transduction is initiated by the absorption of light
by rhodopsin which is composed of a seven transmembrane
domain G-coupled receptor protein, opsin, and the chro-
mophore 11-cis-retinal [54]. Absorption of light changes
the conformation of 11-cis-retinal into all-transretinal. Pho-
toreceptors lack cis-trans isomerase and, therefore, all-trans-
retinal is metabolized into all-trans-retinol and transported4 Journal of Biomedicine and Biotechnology
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Figure 2: Confocal microscopy showing the expression of somato-
statin (SST) in the human retina. As can be appreciated SST
expression (in red) is higher in the RPE than in the neuroretina.
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Figure 3: Confocal microscopy of human RPE showing the
expression of both erythropoietin (Epo) in green and Epo receptor
(Epo-R) in red. At the bottom the merged image shows partial
colocalization of Epo and Epo-R.
to the RPE. In the RPE retinol is reisomerized by means
of cis-trans isomerase to 11-cis-retinal and then redeliv-
ered to the photoreceptors. The protein RPE65 (retinal
pigment epithelium-speciﬁc protein 65kDa) is the protein
responsible for isomerization of the all-trans-retinaldehyde
to its photoactive 11-cis-retinaldehyde and is essential for
the visual cycle. In this regard, it has been shown that
RPE65 mutations cause severe retinal diseases such as Leber
congenital amaurosis [55].
There is a great deal of evidence that the transport of
retinoids between these cellular compartments is mediated
by the interphotoreceptor retinoid-binding protein (IRBP),
a large glycoprotein synthesized in the photoreceptors and
extruded into the interphotoreceptor matrix (IPM) that ﬁlls
the subretinal space [56–58]. IRBP functions to solubilize
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Figure 4: (a) Immunoblot showing higher protein content of
apolipoprotein A1 (apoA1) in RPEs from diabetic donors in
comparison with RPEs from nondiabetic donors. (b) Inmmunoﬂu-
orescent image of apoA1 (red) in ARPE cells (spontaneously
immortalized cell line of human RPE).
retinal and retinol, which are otherwise insoluble in water,
and mediates the targeting of these compounds and deﬁnes
transport direction [59–62]. This role for IRBP is further
supported by the observation that IRBP is not only present
in the IPM but also in endosomes of the RPE [63]. Transport
direction is then deﬁned by the rapid turnover of IRBP
between the IPM and the RPE. Apart from participating in
thevisualcycle,IRBPisimportantinfattyacidtransportand
isessentialtothemaintenanceofthephotoreceptors[58,64].
Recently, it has been demonstrated that lower IRBP
production is an early event in the human diabetic retina
and is associated with retinal neurodegeneration [65, 66].
In addition, the content of cellular retinaldehyde bind-
ing protein (CRALBP), a protein also related to retinoid
metabolism, has been found increased in RPE from diabetic
subjects with no clinically apparent diabetic retinopathy in
comparison with control donors [67].
5. Phagocytosis
Another function in the maintenance of photoreceptor
excitability is the phagocytosis of shed photoreceptor outer
segments [68–70]. Photoreceptors are exposed to intense
levels of light, thus leading to accumulation of photo-
damaged proteins and lipids. Thus, during each day, the
concentration of light-induced toxic substances increasesJournal of Biomedicine and Biotechnology 5
inside the photoreceptors [42]. Light transduction by pho-
toreceptors is dependent on the proper functioning and
structure of proteins, retinal, and membranes. Therefore,
to maintain the excitability of photoreceptors, the photore-
ceptor outer segments (POSs) undergo a constant renewal
process [69, 71, 72]. In this renewal process POSs are newly
built from the base of outer segments, at the cilium. The
tips of the POS that contain the highest concentration of
radicals, photodamaged proteins, and lipids are shed from
the photoreceptors. Through coordinated POSs tip shedding
and the formation of new POS, a constant length of the
POS is maintained. Shed POSs are phagocytosed by the RPE.
In the RPE, shed POS are digested and essential molecules,
such as docosahexaenoic acid and retinal, are redelivered
to photoreceptors to rebuild light-sensitive outer segments
from the base of the photoreceptors [69, 73].
An impairment of phagocytosis has been described in
long term diabetes [74] and, therefore, it is possible that this
could also happen to RPE cells. However, speciﬁc studies
addressed to this issue are needed.
6.Secretion
The RPE is known to produce and to secrete a variety of
growth factors [7, 75] as well as factors that are essential
for the maintenance of the structural integrity of the retina
[76, 77] and choriocapillaris [78]. Thus, the RPE produces
molecules that support the survival of photoreceptors and
ensure a structural basis for the optimal circulation and
supply of nutrients. The RPE is able to secrete pigment
epithelium-derived factor (PEDF) [7, 79, 80], VEGF [7, 81–
85], ﬁbroblast growth factors (FGF-1, FGF-2, and FGF-5)
[7, 86–91], transforming growth factor-β (TGF-β)[ 7, 92–
94], insulin-like growth factor-I (IGF-I) [95, 96], nerve
growth factor (NGF), brain-derived growth factor (BDNF),
neurotropin-3 (NT-3), ciliary neurotrophic factor (CNTF)
[97, 98], platelet-derived growth factor (PDGF) [7, 99,
100], lens epithelium-derived growth factor (LEDGF) [101],
members of the interleukin family [102–104], chemokines,
tumor necrosis factor α (TNF-α), colony-stimulating factors
(CSF), and diﬀerent types of tissue inhibitor of matrix
metalloprotease (TIMP) [105–110]. Among these factors,
PEDF and VEGF seem the most signiﬁcant.
6.1. PEDF and VEGF. In the healthy eye, the RPE secretes
PEDF [7, 80–82], which helps to maintain the retinal as
well as the choriocapillaris structure in two ways. PEDF
was described as a neuroprotective factor because it was
shown to protect neurons against glutamate-induced or
hypoxia-induced apoptosis [76, 111, 112]. In addition,
PEDF was shown to function as an antiangiogenic factor
that inhibited endothelial cell proliferation and stabilized
the endothelium of the choriocapillaris [7, 81, 82]. These
eﬀects on vascularization also play an important role in
the embryonic development of the eye [113, 114]. Using
PEDF-deﬁcient(PEDF−/−)mice,ithasbeenconﬁrmedthat
PEDF is an important modulator of early postnatal retinal
vascularization and that in its absence retinal vascularization
pr oc eedsatafast errat eandismor esusc eptiblet oh yper o xia-
mediated vessel obliteration [115].
Another vasoactive factor synthesized by the RPE is
VEGF, which is secreted in low concentrations by the RPE
in the healthy eye [7, 83, 86] where it prevents endothelial
cell apoptosis and is essential for an intact endothelium of
the choriocapillaris [116]. VEGF also acts as a permeability
factor stabilizing the fenestrations of the endothelium [117].
In a healthy eye, PEDF and VEGF are secreted at opposite
sides of the RPE. PEDF is secreted to the apical side where it
acts on neurons and photoreceptors whereas most of VEGF
is secreted to the basal side where it acts on the choroidal
endothelium [118, 119].
Overproduction of VEGF plays an essential role in the
development of PDR. The pathogenesis of DME remains
to be fully understood but VEGF and proinﬂammatory
cytokines have been involved in its development. Never-
theless, the balance between angiogenic (i.e., VEGF) and
antiangiogenic factors (i.e., PEDF) will be crucial for the
development of DR. In this regard, advanced glycation end
products increase retinal VEGF expression in RPE [120].
Downregulation of PEDF expression by elevated glucose
concentrationinculturedhumanRPEcellswasalsoobserved
[121]. Therefore, strategies in blocking VEGF or stimulating
PEDF have been proposed as new therapeutic approaches for
DR.
Apart from the factors mentioned above, in recent years
new molecules have been found to be synthesized in RPE.
Among them, somatostatin, erythropoietin, and ApoA1
seemtobeofspecialinterestbecausetheycouldopenupnew
therapeutic strategies for the treatment of DR.
6.2. Somatostatin. Somatostatin (SST) is a peptide that was
originally identiﬁed as the hypothalamic factor responsible
for inhibition of the release of growth hormone (GH)
from the anterior pituitary [122]. Subsequent studies have
shown that SST has a much broader spectrum of inhibitory
actions and that it is much more widely distributed in the
body, occurring not only in many regions of the central
nervous system but also in many tissues of the digestive
tract, including the stomach, intestine, and pancreas [123].
SST mediates its multiple biologic eﬀects via speciﬁc plasma
membrane receptors that belong to the family of G-protein-
coupled receptors having seven transmembrane domains. So
far, ﬁve SST receptor subtypes (SSTRs) have been identiﬁed
(SSTRs 1–5) [124].
In the setting of this review it must be pointed out that
SST is produced by the retina of various species, including
humans [125–130]. Furthermore, SSTRs are also expressed
in the retina, with SSTR1 and SSTR2 being the most widely
expressed [127, 131–134]. The production of both SST and
its receptors simultaneously suggests an autocrine action in
the human retina.
The amount of SST produced by the retina is signiﬁcant
as can be deduced by the strikingly high levels found in
the vitreous ﬂuid. In fact, intravitreal levels of SST are
higher than in plasma. It must be emphasized that the
intravitreous level of total proteins is at least 20-fold less6 Journal of Biomedicine and Biotechnology
than in serum [135, 136]. Thus, the higher intravitreal
concentration of a particular protein in relation to its plasma
levels strongly suggests an important rate of intraocular
production. The main source of SST in humans is RPE.
Thus, it has been demonstrated that SST expression and
content is higher in RPE than in the neuroretina (Figure 2)
[137].
The main functions of SST for retinal homeostasis are
the following (1) SST acts as a neuromodulator through
multiple pathways, including intracellular Ca2+ signaling
[138], nitric oxide function [139], and glutamate release
from the photoreceptors [140]. In addition, a loss in
SST immunoreactivity was found after degeneration of the
ganglion cells [141]. It should be noted that retinal ganglion
cells (RGCs) are the earliest cells aﬀected and have the
highestrateofapoptosis indiabetes[137,142].Thiscouldbe
because RGCs are more sensitive to hypoxic conditions and
glutamate excitotoxicity [143]. Therefore, the neuroretinal
damage that occurs in DR might be the reason for the
decreased SST levels detected in the vitreous ﬂuid of these
patients. In fact we have recently found that low SST
expression and production is an early event in DR and is
associated with retinal neurodegeneration (apoptosis and
glial activation) [137]. (2) SST is an angiostatic factor. SST
may reduce endothelial cell proliferation and neovasculari-
sation by multiple mechanisms, including the inhibition of
postreceptor signalling events of peptide growth factors such
as IGF-I, VEGF, epidermal growth factor (EGF), and PDGF
[144].Usingamousemodelofhypoxia-inducedretinopathy,
it has been demonstrated that in retinas overexpressing
subtype 2 receptor of somatostatin (sst2) neovascularization
was lower than in wild type retinas [145]. In addition, also
using a mouse model of hypoxia-induced retinopathy it
has been observed that retinal neovascularization increased
in sst(2)-KO mice [146]. Furthermore, both SSTR2- and
SSTR3-selectiveanaloguesdirectlyinhibitretinalendothelial
cell growth in vitro [147, 148]. It is worthy of mention
that the intravitreal levels of SST lie within the same
range as those showing antiangiogenic eﬀect in experimental
studies [149–151]. Therefore, SST can be considered as
a good candidate to be added to the list of the natural
inhibitors of angiogenesis. (3) SST has been involved in
the transport of water and ions. As previously mentioned,
various ion/water transport systems are located on the apical
side of the RPE, adjacent to the subretinal space, and,
indeed, a high expression of SST-R2 has been shown in this
apical membrane of the RPE [131]. Nevertheless, the speciﬁc
mechanisms involved in ion/water transport driven by SST
remain to be elucidated.
In DR there is a downregulation of SST that is associated
with retinal neurodegeneration [137] .T h u s ,al o w e re x p r e s -
sion of SST has been found in RPE and neuroretina as well
as a dramatic decrease of intavitreal SST levels [137, 152–
154]. As a result, the physiological role of SST in preventing
both neovascularisation and ﬂuid accumulation within the
retina is reduced, and consequently the development of
PDR and DME is favoured [153, 154]. In addition, the loss
of neuromodulator activity also contributes to neuroretinal
damage. For all these reasons, intravitreal injection of SST
analogues or gene therapy has been proposed as a new
therapeutic approach in DR [155].
6.3. Erythropoietin. Erythropoietin (Epo) was ﬁrst described
as a glycoprotein produced exclusively in fetal liver and adult
kidney that acts as a major regulator of erythropoiesis [156].
However, Epo expression has also been found in the human
brain [157] and in the human fetal retina [158]. In recent
years, we have demonstated that not only Epo but also its
receptor (Epo-R) is expressed in the adult human retina
(Figure 3)[159,160].EpoandEpoRmRNAsaresigniﬁcantly
higher in RPE than in the neuroretina [160].
Inaddition,intravitreallevelsofEpoare∼3.5-foldhigher
than those found in plasma [159] .T h er o l eo fE p oi nt h e
retina remains to be elucidated but it seems that it has a
potent neuroprotective eﬀect [161, 162]. In this regard, it
has been shown that Epo protects cultured neurons from
hypoxia and glutamate toxicity [163–165], and its systemic
administration reduces neuronal injury in animal models
of focal ischemic stroke and inﬂammation [166–168]. In
addition,ithasbeendemonstratedusinganinvitromodelof
bovine blood-brain barrier (BBB) that Epo protects against
the VEGF-induced permeability of the BBB and restores the
tight junction proteins [169]. Since BRB is structurally and
functionally similar to the BBB [170], it is possible that
Epo could act as an antipermeability factor in the retina. In
fact, Epo was able to improve DME when administered for
treatment of anemia in diabetic patients with renal failure
[171].
Epo is upregulated in DR [159, 160, 172, 173]. Epo
overexpression has been found in both the RPE and neu-
roretina of diabetic eyes [159, 160]. This is in agreement
withtheelevatedconcentrationsofEpofoundinthevitreous
ﬂuid of diabetic patients (∼30-fold higher than plasma
and ∼10-fold higher than in non diabetic subjects) [159].
Hypoxia is a major stimulus for both systemic [156]a n d
intraocular Epo production [174]. In fact, high intravitreous
levels of Epo have recently been reported in ischemic retinal
diseases such as PDR [159, 172, 173, 175]. In addition,
it has been reported that Epo has an angiogenic potential
equivalent to VEGF [173, 176]. Therefore, Epo could be an
important factor involved in stimulating retinal angiogenesis
in PDR. However, intravitreal levels of Epo have been found
at a similar range in PDR to that in DME (a condition
in which hypoxia is not a predominant event) [159]. In
addition, intravitreal Epo levels are not elevated in non
diabetic patients with macular edema secondary to retinal
vein occlusion [177]. Finally, a higher expression of Epo
has been detected in the retinas from diabetic donors at
early stages of DR in comparison with non diabetic donors,
and this overexpression is unrelated to mRNA expression
of hypoxic inducible factors (HIF-1α and HIF-1β)[ 160].
Therefore, stimulating agents other than hypoxia/ischemia
are involved in the upregulation of Epo that exists in the
diabetic eye.
The reason why Epo is increased in DR remains to be
elucidated but the bulk of the available information points
to a protective eﬀect rather than a pathogenic eﬀect, at
least in the early stages of DR. There have been severalJournal of Biomedicine and Biotechnology 7
reports on the protective eﬀects of Epo in the retina
[175, 178–185]. In addition, Epo is a potent physiologic
stimulus for the mobilization of endothelial progenitor cells
(EPCs) [186] and, therefore, it could play a relevant role
in regulating the traﬃc of circulating EPCs towards injured
retinal sites. Recruitment of EPCs to the pathologic area
would be beneﬁcial because their capability of integrating
into damaged vasculature can lead to the reendothelization
of acellular vessels. It has recently been shown that a
reduction of EPCs exists in nonproliferarive DR [187] and it
has also been demonstrated that EPCs from diabetic donors
are less eﬀective in repairing damaged vasculature [188].
In this regard, the increase of intraocular synthesis of Epo
that occurs in early stages of DR (i.e., in nonproliferative
DR) can be contemplated as a compensatory mechanism for
repairing the damage induced by the diabetic milieu through
an increase in EPC recruitment. However, in advanced stages
of DR (i.e., in the setting of PDR) a dramatic increase of
both VEGF [7] and mature EPCs has been detected [187].
In this setting, Epo could potentiate the eﬀects of VEGF,
thuscontributingtoneovascularisationand,inconsequence,
worsening PDR [181, 189].
The potential advantages of Epo or EpoR agonists in
the treatment of DR include neuroprotection, vessel stability,
and enhanced recruitment of EPCs to the pathological area.
However, as mentioned above, timing is critical since if
Epo is given at later hypoxic stages, the severity of DR
could even increase. However, in the case of the eye, disease
progression is easy to follow without invasive investigation
and allows timing of the administration of drugs to be
carefully monitored, hopefully resulting in better clinical
outcomes.
6.4. Apolipoprotein A1. Apolipoprotein A1 (apoA1) has been
recently proposed as a key factor for intraretinal reverse
transport of lipids, thus preventing lipid accumulation in
the retina [190]. In a proteomic analysis of human vitreous
ﬂuidwefoundthatapoA1washighlyintraocularlyproduced
in patients with proliferative DR in comparison with non-
diabetic subjects [65]. In addition, we have recently shown
higher apoA1 (both mRNA levels and protein) in the retinas
from diabetic donors in comparison with non-diabetic
donors (Figure 4)[ 191, 192]. Moreover, apoA1 immunoﬂu-
orescence was detected in all retinal layers but mRNA was
more abundant in RPE [55]. This ﬁnding suggests that
RPE is the main source of apoA1 in the human retina.
These results are consistent with those reported by Li et al.
[193]whichdemonstratedtheimmunolocalizationofapoA1
to Bruch’s membrane (a thin connective tissue between
the basal surface of the RPE and the choriocapillaris) in
postmortem human eye specimens as well as the presence
of apoA1 transcripts in the RPE and neural retina. Several
independent lines of research indicate that the RPE contains
LDL receptors (LDLRs) and/or scavenger receptors by which
lipoproteins (LDL) are internalized and serve as a signiﬁcant
supply of lipids to the retina [194–196]. Taken together, the
RPE, due to its capacity in internalizing and extruding lipids,
can be considered as the most important regulator of lipid
transport in the retina.
The reason why apoA1 is overexpressed in the diabetic
retina needs to be elucidated but one possibility is that the
diabetic milieu stimulates apoA1 production by the retina.
In this regard, Kawai et al. [197] observed an increased
secretion of apoA1 from the main lacrimal gland in patients
with DR, but it was not detected in healthy subjects. In
recent years new insights have been gained into the transport
of lipids within the retina [190, 194], thus allowing us to
hypothesizethatthemechanismsregulatingintraretinallipid
transport rather than serum levels are more important in
the pathogenesis of DR [191, 192, 198]. In this regard,
ABCA (ATP binding cassette transporter A1) and apoA1
have been found in several layers of monkey retina, thus
suggesting the existence of an intraretinal mechanism to
export HDL-like particles [190]. Ishida et al. [199]h a v e
demonstratedthatHDLstimulatestheeﬄuxofradiolabelled
lipids, of photoreceptor outer segment origin, from the
basal surface of RPE cells in culture. The role of this HDL-
based intraretinal lipid transport could be important in
preventing lipotoxicity. The fact that the retina is the only
neural tissue that has a direct and frequent exposure to light
presents a signiﬁcant problem. This is because many lipids,
especially polyunsaturated fatty acids (which are mainly
located in the photoreceptor outer segments) and cholesterol
esters, are highly susceptible to photo-oxidation and these
oxidized lipids become extremely toxic to retinal cells [40].
In DR, this problem could be aggravated by the increase
of oxidative stress and lipid peroxidation associated with
diabetes. Apart from preventing or arresting lipotoxicity,
apoA1 is a potent scavenger of reactive oxygen species
[200, 201]; therefore, it could play an important role in
protecting the retina from the overall oxidative stress due to
diabetes. In this regard, it should be noted that retinopathy
has been associated with apoA1 deﬁciency of genetic origin
[202, 203].
Lipoprotein deposition plays an essential role in the
pathogenesis of age-related macular degeneration (ARMD)
[204,205],butlittleisknownabouttheoriginoflipoproteins
in the retina of diabetic patients and their potential role
in the pathogenesis of DR. The role of apoA1 in extruding
lipids out of the retina permits us to hypothesize that
apoA1 is increased in diabetic patients as a compensatory
mechanism in order to prevent the development of DR [67].
In other words, those diabetic patients with less capacity for
apoA1 production by the retina would be more prone to
develop lipid deposition (hard exudates) in the retina and,
in consequence, to initiate DR.
Given that apoA1 has antioxidant properties and pre-
vents lipid deposition in the retina, the design of new treat-
ment strategies addressed to promoting the overexpression
of apoA1 in order to reduce the development of DR seems
warranted.
7. Concluding Remarks
The RPE lies in the interface between the neural retina
and the choriocapillaris where it forms the outer BRB. To
retard transepithelium diﬀusion between cells, the cells of
the epithelium are bound together by a partially occluding8 Journal of Biomedicine and Biotechnology
seal, the tight junction. The tight junction subdivides the
plasma membrane into two functionally distinct domains.
The apical membrane faces the photoreceptors of the neural
retina, while the basolateral membrane faces the fenestrated
choriochapillaris.
As a layer of pigmented cells the RPE absorbs the
light energy focused by the lens on the retina. To regulate
transport across the monolayer, various pumps, channels,
and transporters are distributed speciﬁcally to either the
apical or the basolateral membrane. The RPE transports
ions, water, and metabolic end products from the subretinal
space to the blood and, conversely, takes up nutrients such as
glucose, retinol, and fatty acids from the blood and delivers
these nutrients to the photoreceptors. To maintain photore-
ceptor excitability retinal is constantly transported from the
photoreceptors to the RPE where it is reisomerized to 11-cis-
retinal and transported back to the photoreceptors. This is
the key component of the visual cycle. Another function that
contributes to the maintenance of photoreceptor excitability
isthephagocytosisoftheshedphotoreceptoroutersegments.
The photoreceptor outer segments are digested, and essential
substances such as retinal are recycled and returned to the
photoreceptors for rebuilding light-sensitive outer segments
from the base of the photoreceptors. In addition, the RPE
is able to secrete a variety of growth factors as well as
factorsthatareessentialforthemaintenanceofthestructural
integrity of the retina and the choriocapillaris. Furthermore,
the secretory activity of the RPE plays an important role in
establishing the immune privilege of the eye by secreting
immunosuppressive factors.
Most investigations into the pathogenesis of DR have
been concentrated on the neural retina since this is where
clinical lesions are manifested. However, RPE is essential for
neuroretina survival and, consequently, for visual function.
In recent years, various abnormalities in both the struc-
tural and secretory functions of RPE have been found in
DR. Therefore, future scenarios involving new therapeutic
strategies addressed to modulating RPE impairment are
warranted.
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